Skip to main content
Top
Published in: Inflammation 2/2008

01-04-2008

The Treatment with Antibody of TNF-α Reduces the Inflammation, Necrosis and Fibrosis in the Non-alcoholic Steatohepatitis Induced by Methionine- and Choline-deficient Diet

Authors: Suleyman Serdar Koca, Ibrahim Halil Bahcecioglu, Orhan Kursat Poyrazoglu, Ibrahim Hanifi Ozercan, Kazim Sahin, Bilal Ustundag

Published in: Inflammation | Issue 2/2008

Login to get access

Abstract

To assess the effects of anti-TNF-α antibody (infliximab) in experimental steatohepatitis induced by methionine- and choline-deficient (MCD) diet. The study included thirty rats. One group received normal rat food, and two groups received MCD diet. The treatment group received a single dose intra-peritoneal infliximab (4 mg/kg), at week 8. MCD diet increased levels of AST, ALT, TNF-α, TGF-β1, tissue and plasma MDA (p < 0.05 for each). Moreover, it led to steatosis, ballooning degeneration, inflammation, fibrosis and increased actin expression, histopathologically (p < 0.05 for each). In this experimental steatohepatitis anti-TNF-α antibody decreased the levels of AST, ALT, TGF-β1 and plasma and tissue MDA (p < 0.05 for each). Moreover, inflammation, necrosis, actin expression and fibrosis decreased in anti-TNF-α group compared to placebo group (p < 0.05 for each). This study indicates that anti-TNF-α antibody is effective on necrosis, inflammation and fibrosis in the experimental model of non-alcoholic steatohepatitis, induced by MCD diet.
Literature
1.
go back to reference Diehl, A. M. 1999. Nonalcoholic steatohepatitis. Semin. Liver Dis. 19:221–229.PubMed Diehl, A. M. 1999. Nonalcoholic steatohepatitis. Semin. Liver Dis. 19:221–229.PubMed
2.
go back to reference Ingue, F. Y., M. Z. Younossi, G. Marchosini, and T. A. McCullough. 2001. Clinical features and natural history of non-alcoholic steatosis syndromes. Semin. Liver Dis. 75:733–739. Ingue, F. Y., M. Z. Younossi, G. Marchosini, and T. A. McCullough. 2001. Clinical features and natural history of non-alcoholic steatosis syndromes. Semin. Liver Dis. 75:733–739.
3.
go back to reference Koteish, A., and A. M. Diehl. 2002. Animal models of steatohepatitis. Best Pract. Res. Clin. Gastroenterol. 16:679–690.PubMedCrossRef Koteish, A., and A. M. Diehl. 2002. Animal models of steatohepatitis. Best Pract. Res. Clin. Gastroenterol. 16:679–690.PubMedCrossRef
4.
go back to reference Harrison, S. A., S. Kadakia, K. Lang, and S. Schenker. 2002. Non-alcoholic steatohepatitis: what we know in the new millenium. Am. J. Gastroenterol. 97:2714–2724.PubMed Harrison, S. A., S. Kadakia, K. Lang, and S. Schenker. 2002. Non-alcoholic steatohepatitis: what we know in the new millenium. Am. J. Gastroenterol. 97:2714–2724.PubMed
5.
go back to reference Day, C. P., and O. F. James. 1998. Steatohepatitis: a tale of two ‘hits’? Gastroenterology 114:842–845.PubMedCrossRef Day, C. P., and O. F. James. 1998. Steatohepatitis: a tale of two ‘hits’? Gastroenterology 114:842–845.PubMedCrossRef
6.
go back to reference Ikejima, K., Y. Takei, H. Honda, M. Hirose, M. Yoshikawa, Y. J. Zhang, T. Lang, T. Fukuda, S. Yamashina, T. Kitamura, and N. Sato. 2002. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 122:1399–1410.PubMedCrossRef Ikejima, K., Y. Takei, H. Honda, M. Hirose, M. Yoshikawa, Y. J. Zhang, T. Lang, T. Fukuda, S. Yamashina, T. Kitamura, and N. Sato. 2002. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 122:1399–1410.PubMedCrossRef
7.
go back to reference Atzeni, F., P. Sarzi-Puttini, A. Doria, L. Iaccarino, and F. Capsoni. 2005. Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. Autoimmun. Rev. 4:144–152.PubMedCrossRef Atzeni, F., P. Sarzi-Puttini, A. Doria, L. Iaccarino, and F. Capsoni. 2005. Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. Autoimmun. Rev. 4:144–152.PubMedCrossRef
8.
go back to reference Markham, A., and H. M. Lamb. 2000. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 59:1341–1359.PubMedCrossRef Markham, A., and H. M. Lamb. 2000. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 59:1341–1359.PubMedCrossRef
9.
go back to reference Czaja, M. J., J. Xu, and E. Alt. 1995. Prevention of carbon tetrachloride-induced rat liver injury by tumour necrosis factor receptor. Gastroenterology 108:1849–1854.PubMedCrossRef Czaja, M. J., J. Xu, and E. Alt. 1995. Prevention of carbon tetrachloride-induced rat liver injury by tumour necrosis factor receptor. Gastroenterology 108:1849–1854.PubMedCrossRef
10.
go back to reference Hishinuma, I., J. Nagakawa, K. Hirota, K. Miyamoto, K. Tsukidate, T. Yamanaka, K. Katayama, and I. Yamatsu. 1990. Involvement of tumor necrosis factor-alpha in development of hepatic injury in galactosamine-sensitized mice. Hepatology 12:1187–1191.PubMedCrossRef Hishinuma, I., J. Nagakawa, K. Hirota, K. Miyamoto, K. Tsukidate, T. Yamanaka, K. Katayama, and I. Yamatsu. 1990. Involvement of tumor necrosis factor-alpha in development of hepatic injury in galactosamine-sensitized mice. Hepatology 12:1187–1191.PubMedCrossRef
11.
go back to reference Iimuro, Y., R. M. Gallucci, M. I. Luster, H. Kono, and R. G. Thurman. 1997. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. J. Hepatol. 26:1530–1537.CrossRef Iimuro, Y., R. M. Gallucci, M. I. Luster, H. Kono, and R. G. Thurman. 1997. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. J. Hepatol. 26:1530–1537.CrossRef
12.
go back to reference Tilg, H., R. Jalan, A. Kaser, N. A. Davies, F. A. Offner, S. J. Hodges, O. Ludwiczek, D. Shawcross, H. Zoller, A. Alisa, R. P. Mookerjee, I. Graziadei, C. Datz, M. Trauner, D. Schuppan, P. Obrist, W. Vogel, and R. Williams. 2003. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J. Hepatol. 38:419–425.PubMedCrossRef Tilg, H., R. Jalan, A. Kaser, N. A. Davies, F. A. Offner, S. J. Hodges, O. Ludwiczek, D. Shawcross, H. Zoller, A. Alisa, R. P. Mookerjee, I. Graziadei, C. Datz, M. Trauner, D. Schuppan, P. Obrist, W. Vogel, and R. Williams. 2003. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J. Hepatol. 38:419–425.PubMedCrossRef
13.
go back to reference Leclercq, I. A., G. C. Farrell, J. Field, D. R. Bell, F. J. Gonzalez, and G. R. Robertson. 2000. CYP2EI and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J. Clin. Invest. 105:1067–1075.PubMedCrossRef Leclercq, I. A., G. C. Farrell, J. Field, D. R. Bell, F. J. Gonzalez, and G. R. Robertson. 2000. CYP2EI and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J. Clin. Invest. 105:1067–1075.PubMedCrossRef
14.
go back to reference Ustundag, B., I. H. Bahcecioglu, K. Sahin, S. Duzgun, S. Koca, F. Gulcu, and I. H. Ozercan. 2007. Protective effect of soy isoflavones and activity levels of plasma paraoxonase and arylesterase in the experimental nonalcoholic steatohepatitis model. Dig. Dis. Sci. 52:2006–2014.PubMedCrossRef Ustundag, B., I. H. Bahcecioglu, K. Sahin, S. Duzgun, S. Koca, F. Gulcu, and I. H. Ozercan. 2007. Protective effect of soy isoflavones and activity levels of plasma paraoxonase and arylesterase in the experimental nonalcoholic steatohepatitis model. Dig. Dis. Sci. 52:2006–2014.PubMedCrossRef
15.
go back to reference Satoh, K., S. Takamatsu, S. Sakuta, S. Mizuno, H. Metoki, and M. Takamatsu. 1981. Augmented malondialdehyde production by platelets from patients with cerebrovascular disorders. Jpn. Circ. J. 45:1335–1341.PubMed Satoh, K., S. Takamatsu, S. Sakuta, S. Mizuno, H. Metoki, and M. Takamatsu. 1981. Augmented malondialdehyde production by platelets from patients with cerebrovascular disorders. Jpn. Circ. J. 45:1335–1341.PubMed
16.
go back to reference Yagi, K.. 1984. Assay for blood plasma or serum. Methods Enzymol. 105:328–331.PubMed Yagi, K.. 1984. Assay for blood plasma or serum. Methods Enzymol. 105:328–331.PubMed
17.
go back to reference Ohkawa, H., N. Ohishi, and K. Yagi. 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95:351–358.PubMedCrossRef Ohkawa, H., N. Ohishi, and K. Yagi. 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95:351–358.PubMedCrossRef
18.
go back to reference Brunt, E., C. Janney, A. M. Bisceglie, B. A. Neuschwander-Tetri, and B. R. Bacon. 1999. Nonalcoholic steatohepatitis; a proposal for grading and staging the histopathologic lesions. Am. J. Gastroenterol. 94:2467–2474.PubMedCrossRef Brunt, E., C. Janney, A. M. Bisceglie, B. A. Neuschwander-Tetri, and B. R. Bacon. 1999. Nonalcoholic steatohepatitis; a proposal for grading and staging the histopathologic lesions. Am. J. Gastroenterol. 94:2467–2474.PubMedCrossRef
19.
go back to reference Nanji, A. A., E. K. Yang, F. Fogt, S. M. H. Sadrzadeh, and A. J. Dannenberg. 1996. Medium chain triglycerides and vitamin E reduce the severity of established experimental alcoholic liver disease. J. Pharmacol. Exp. Ther. 277:1694–1699.PubMed Nanji, A. A., E. K. Yang, F. Fogt, S. M. H. Sadrzadeh, and A. J. Dannenberg. 1996. Medium chain triglycerides and vitamin E reduce the severity of established experimental alcoholic liver disease. J. Pharmacol. Exp. Ther. 277:1694–1699.PubMed
20.
go back to reference Kirsch, R., V. Clarkson, E. G. Shephard, D. A. Marais, M. A. Jaffer, V. E. Woodburne, R. E. Kirsch, and P. L. Hall. 2003. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J. Gastroenterol. Hepatol. 18:1272–1282.PubMedCrossRef Kirsch, R., V. Clarkson, E. G. Shephard, D. A. Marais, M. A. Jaffer, V. E. Woodburne, R. E. Kirsch, and P. L. Hall. 2003. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J. Gastroenterol. Hepatol. 18:1272–1282.PubMedCrossRef
21.
go back to reference Lee, K. S., S. J. Lee, H. J. Park, J. P. Chung, K. H. Han, C. Y. Chon, S. I. Lee, and Y. M. Moon. 2001. Oxidative stress effect on the activation of hepatic stellate cells. Yonsei Med. J 42:1–8.PubMed Lee, K. S., S. J. Lee, H. J. Park, J. P. Chung, K. H. Han, C. Y. Chon, S. I. Lee, and Y. M. Moon. 2001. Oxidative stress effect on the activation of hepatic stellate cells. Yonsei Med. J 42:1–8.PubMed
22.
go back to reference Liu, X. J., L. Yang, Y. Q. Mao, Q. Wang, M. H. Huang, Y. P. Wang, and H. B. Wu. 2002. Effects of the tyrosine protein kinase inhibitor genistein on the proliferation, activation of cultured rat hepatic stellate cells. World J. Gastroenterol. 8:739–745.PubMed Liu, X. J., L. Yang, Y. Q. Mao, Q. Wang, M. H. Huang, Y. P. Wang, and H. B. Wu. 2002. Effects of the tyrosine protein kinase inhibitor genistein on the proliferation, activation of cultured rat hepatic stellate cells. World J. Gastroenterol. 8:739–745.PubMed
23.
go back to reference Chawla, R. K., W. H. Watson, C. E. Eastin, E. Y. Lee, J. Schmidt, and C. J. McClain. 1998. S-adenosylmethionine deficiency and TNF-alpha in lipopolysaccharide-induced hepatic injury. Am. J. Physiol. 275:G125–129.PubMed Chawla, R. K., W. H. Watson, C. E. Eastin, E. Y. Lee, J. Schmidt, and C. J. McClain. 1998. S-adenosylmethionine deficiency and TNF-alpha in lipopolysaccharide-induced hepatic injury. Am. J. Physiol. 275:G125–129.PubMed
24.
go back to reference Ghoshal, A. K., M. Ahluwalia, and E. Farber. 1983. The rapid induction of liver cell death in rats fed a choline-deficient methionine-low diet. Am. J. Pathol. 113:309–314.PubMed Ghoshal, A. K., M. Ahluwalia, and E. Farber. 1983. The rapid induction of liver cell death in rats fed a choline-deficient methionine-low diet. Am. J. Pathol. 113:309–314.PubMed
25.
go back to reference Hensley, K., Y. Kotake, and H. Sang. 2001. Dietary choline restriction causes complex I dysfunction and increased H(2)O(2) generation in liver mitochondria. Carcinogenesis 21:983–989.CrossRef Hensley, K., Y. Kotake, and H. Sang. 2001. Dietary choline restriction causes complex I dysfunction and increased H(2)O(2) generation in liver mitochondria. Carcinogenesis 21:983–989.CrossRef
26.
go back to reference George, J., N. Pera, N. Phung, I. Leclercq, J. Yun Hou, and G. Farrell. 2003. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J. Hepatol. 39:756–764.PubMedCrossRef George, J., N. Pera, N. Phung, I. Leclercq, J. Yun Hou, and G. Farrell. 2003. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J. Hepatol. 39:756–764.PubMedCrossRef
27.
go back to reference Simeonova, P. P., R. M. Gallucci, T. Hulderman, R. Wilson, C. Kommineni, M. Rao, and M. I. Luster. 2001. The role of tumor necrosis factor-alpha in liver toxicity, inflammation, and fibrosis induced by carbon tetrachloride. Toxicol. Appl. Pharmacol. 177:112–120.PubMedCrossRef Simeonova, P. P., R. M. Gallucci, T. Hulderman, R. Wilson, C. Kommineni, M. Rao, and M. I. Luster. 2001. The role of tumor necrosis factor-alpha in liver toxicity, inflammation, and fibrosis induced by carbon tetrachloride. Toxicol. Appl. Pharmacol. 177:112–120.PubMedCrossRef
28.
go back to reference Crespo, J., A. Cayon, P. Fernandez-Gil, M. Hernandez-Guerra, M. Mayorga, A. Dominguez-Diez, J. C. Fernandez-Escalante, and F. Pons-Romero. 2001. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34:1158–1163.PubMedCrossRef Crespo, J., A. Cayon, P. Fernandez-Gil, M. Hernandez-Guerra, M. Mayorga, A. Dominguez-Diez, J. C. Fernandez-Escalante, and F. Pons-Romero. 2001. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34:1158–1163.PubMedCrossRef
29.
go back to reference Kugelmas, M., D. B. Hill, B. Vivian, L. Marsano, and C. J. McClain. 2003. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38:413–419.PubMedCrossRef Kugelmas, M., D. B. Hill, B. Vivian, L. Marsano, and C. J. McClain. 2003. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38:413–419.PubMedCrossRef
30.
go back to reference Satapathy, S. K., S. Garg, R. Chauhan, P. Sakhuja, V. Malhotra, B. C. Sharma, and S. K. Sarin. 2004. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99:1946–1652.PubMedCrossRef Satapathy, S. K., S. Garg, R. Chauhan, P. Sakhuja, V. Malhotra, B. C. Sharma, and S. K. Sarin. 2004. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99:1946–1652.PubMedCrossRef
31.
go back to reference Koppe, S. W., A. Sahai, P. Malladi, P. F. Whitington, and R. M. Green. 2004. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J. Hepatol. 41:592–598.PubMedCrossRef Koppe, S. W., A. Sahai, P. Malladi, P. F. Whitington, and R. M. Green. 2004. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J. Hepatol. 41:592–598.PubMedCrossRef
32.
go back to reference Strieter, R. M., D. G. Remick, P. A. Ward, R. N. Spengler, J. P. Lynch, J. Larrick, and S. L. Kunkel. 1988. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem. Biophys. Res. Commun. 155:1230–1236.PubMedCrossRef Strieter, R. M., D. G. Remick, P. A. Ward, R. N. Spengler, J. P. Lynch, J. Larrick, and S. L. Kunkel. 1988. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem. Biophys. Res. Commun. 155:1230–1236.PubMedCrossRef
33.
go back to reference Edwards, M. J., B. J. Keller, F. C. Kaufman, and R. G. Thurman. 1993. The involvement of kupffer cells in carbon tetrachloride toxicity. Toxicol. Appl. Pharmacol. 119:275–279.PubMedCrossRef Edwards, M. J., B. J. Keller, F. C. Kaufman, and R. G. Thurman. 1993. The involvement of kupffer cells in carbon tetrachloride toxicity. Toxicol. Appl. Pharmacol. 119:275–279.PubMedCrossRef
34.
go back to reference Bissell, D. M., D. Roulot, and J. George. 2001. Transforming growth factor beta and the liver. Hepatology 34:859–867.PubMedCrossRef Bissell, D. M., D. Roulot, and J. George. 2001. Transforming growth factor beta and the liver. Hepatology 34:859–867.PubMedCrossRef
35.
go back to reference Li, Z., S. Yang, H. Lin, J. Huang, P. A. Watkins, A. B. Moser, C. Desimone, X. Y. Song, and A. M. Diehl. 2003. Probiotics and antibodies to TNF inhibit inflammatory activity and improve non-alcoholic fatty liver disease. J. Hepatol. 37:343–350.CrossRef Li, Z., S. Yang, H. Lin, J. Huang, P. A. Watkins, A. B. Moser, C. Desimone, X. Y. Song, and A. M. Diehl. 2003. Probiotics and antibodies to TNF inhibit inflammatory activity and improve non-alcoholic fatty liver disease. J. Hepatol. 37:343–350.CrossRef
Metadata
Title
The Treatment with Antibody of TNF-α Reduces the Inflammation, Necrosis and Fibrosis in the Non-alcoholic Steatohepatitis Induced by Methionine- and Choline-deficient Diet
Authors
Suleyman Serdar Koca
Ibrahim Halil Bahcecioglu
Orhan Kursat Poyrazoglu
Ibrahim Hanifi Ozercan
Kazim Sahin
Bilal Ustundag
Publication date
01-04-2008
Publisher
Springer US
Published in
Inflammation / Issue 2/2008
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-007-9053-z

Other articles of this Issue 2/2008

Inflammation 2/2008 Go to the issue